Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024
Galderma (SWX:GALD), the pure-play dermatology category leader, announced today it will be showcasing updates from across its industry-leading dermatology portfolio at the 33rd European Academy of Dermatology and Venereology (EADV) congress taking place in Amsterdam, September 25-28, 2024, reinforcing its commitment to advancing dermatology for every skin story. In addition to presenting 30 abstracts with data on prurigo nodularis, atopic dermatitis, sensitive skin and acne, Galderma will host a series of events dedicated to addressing the real needs of patients and connecting with the dermatology community, including a symposium and several industry hub sessions and Meet the Experts sessions at the Galderma booth.
“EADV is such an important opportunity for us to connect with the community so we can share updates and facilitate discussions that will accelerate science in dermatology. This year, our congress program, including the presentation of new data on nemolizumab in both prurigo nodularis and atopic dermatitis, underscores our leading position in the field and highlights the power of our unique, integrated dermatology strategy.” BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA |
Deep diving on nemolizumab data in prurigo nodularis and atopic dermatitis
Galderma will be presenting nine abstracts on its monoclonal antibody nemolizumab. These include three late-breaking presentations, one on its durability in prurigo nodularis on Wednesday 25 September at 2:15 – 2:30 pm CET and two on its long-term efficacy and transcriptomics data in atopic dermatitis on Wednesday 25 September at 3 – 3:15 pm CET and 4:30 – 4:45 pm CET, respectively. Additional data will be presented on nemolizumab’s speed of onset in prurigo nodularis, immunogenicity profile, and dosing.
The symposium and industry hub session for healthcare professionals will also explore the unmet needs in prurigo nodularis and atopic dermatitis, including the impact of itch, reinforcing Galderma’s ongoing commitment to addressing the most burdensome symptom of both diseases.1,2 The industry hub session, titled “From neglect to necessity: Elevating itch monitoring in atopic dermatitis and prurigo nodularis” will be held on Thursday, September 26, 4:15-5:00 PM CET (Hub 1.09) and hosted by Prof. Jonathan Silverberg, Prof. Shawn Kwatra, and Prof. Martin Metz. The symposium, titled "Shifting the paradigm in the management of atopic dermatitis and prurigo nodularis: Expert insights into the unmet need for itch control” will take place on Friday, September 27, 1:00-2:00 PM CET (Room 7.2). It will be chaired by Prof. Diamant Thaçi, featuring guest speakers Prof. Sonja Ständer, Dr. Sarina Elmariah, and Dr. Andrew Pink.
Showcasing best-in-class science across the full spectrum of dermatology
Galderma will also host an event to share updates from its Global Sensitive Skincare Faculty (GSSF), a first-of-its-kind global community of experts dedicated to creating a better life for people with sensitive skin. Since its inception in 2022, the GSSF has promoted the advancement of sensitive skin science, establishing sensitive skin as a distinct and complex condition. During this session, chaired by Prof. Giovanni Pellacani, experts will share data and trends from the most extensive global epidemiological survey ever conducted - with more than 16,000 subjects - and discuss how this research can be applied in clinical practice. The industry hub session titled “Decoding sensitive skin: Revolutionary and unexpected findings from the broadest worldwide profiling survey” will take place on Thursday, September 26, 2:15-3:00 PM CET (Hub 1.07).
An industry hub session titled “New Skin Quality Assessment Scale – Looking Beyond the Disease” will delve into a new tool Galderma has developed to accurately assess and improve skin quality. The event will take place on Thursday, September 26, 3:15-4:00 PM CET (Hub 1.08).
Finally, attendees interested in acne management can learn more during the dedicated industry hub session “OneAcne: A holistic management approach to improve treatment outcomes in acne, acne sequelae and skin quality”, which will be taking place on Friday, September 27, 3:15-4:00 PM CET (Hub 1.14). Participants will be invited to explore Galderma’s integrated approach in acne management and its unique portfolio of tools from across the dermatology spectrum combined to manage the individual needs of acne patients, from acne prone skin, through breakouts, to scarring.
More details on Galderma’s scientific presentations at EADV can be found here.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
References:
- Pereira MP, et al. Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need. J Eur Acad Dermatol Venereol. 2018;32(12):2224-2229. doi:10.1111/jdv.15107
- Silverberg JI, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340-347. doi:10.1016/j.anai.2018.07.006
View source version on businesswire.com: https://www.businesswire.com/news/home/20240916437749/en/
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Sébastien Cros
Corporate Communications Director
sebastien.cros@galderma.com
+41 79 529 59 85
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hoffmann Green Strengthens Its Intellectual Property With European Patent for H-EVA Cement25.3.2025 18:00:00 CET | Press Release
Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative clinker-free cements, today announces the granting of a European patent for its H-EVA 0% clinker cement. This strategic achievement is in line with Hoffmann Green's dynamic international expansion and marks a new stage in the protection of its intellectual property. After more than 6 years of instruction, the H-EVA patent, validated by the European Patent Office under number EP 18 812 243.6, illustrates the added value of the company's Research & Development model, reinforcing its advanced positioning in the decarbonized cement market. Main characteristics of the H-EVA breakthrough technology: Alkali-ettringitic cement; Cement without clinker (0%); Cement in the form of a powder that can be stored in a silo, just like traditional cement; Perfect compatibility
HyperLight Launches 110GHz Intensity Modulator with Record low Vπ, Leveraging Its TFLN Chiplet ™ Platform25.3.2025 17:00:00 CET | Press Release
HyperLight, creator of the TFLN Chiplet™ platform, today announced the launch of its groundbreaking 110 GHz Low Vπ Intensity Modulator, featuring industry-standard optical fiber and microwave connectors. This industry-first device significantly advances electro-optic modulation capabilities for critical applications, including 400 Gbps-per-lane testing, 100 GHz+ photodiode calibration, high-frequency radio-over-fiber systems, and various other cutting-edge technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325461709/en/ HyperLight's New 110 GHz Low Vπ Intensity Modulator with Record Low 1.4V Half-Wave Voltage Leveraging HyperLight's proprietary TFLN Chiplet™ platform, this revolutionary modulator achieves an unprecedented half-wave voltage (Vπ) of just 1.4 V with bandwidth performance exceeding 110 GHz—setting a new benchmark in high-bandwidth modulation. Combining ultra-low Vπ with minimal insertion loss and ex
Neural Potential: Mouser Series Explores Brain Computer Interfaces at the Intersection of Technology and the Mind25.3.2025 16:18:00 CET | Press Release
Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, today announced the release of the latest installment of the Empowering Innovation Together(EIT) technology series, which examines the rapidly evolving field of brain-computer interfaces (BCIs). This series takes a deep dive into the engineering challenges and opportunities in the development of mind-controlled systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325376038/en/ BCIs create direct communication between the brain and external devices, enabling applications like motor function restoration for individuals with paralysis, speech enhancement for those with communication impairments, and even cognitive augmentation. These systems rely on electrode-based neural signal acquisition and advanced signal processing algorithms to translate brain activity into actionable commands. In th
New Milestone as Sweden Enshrines Policy That Can Turn World Smoke-Free25.3.2025 15:57:00 CET | Press Release
Sweden has enshrined tobacco harm reduction in public health policy after becoming the first nation to prove it’s the most effective path to a smoke-free future. Thanks to Sweden’s stance on safer nicotine alternatives, just 4.5% of Swedish-born adults now smoke - below the 5% smoke-free threshold. This success has led Parliament to formally adopt harm reduction, reinforcing Sweden’s role as a global leader in public health innovation. Dr. Delon Human, leader of Smoke Free Sweden, says: “Swedes have participated in a long-running harm reduction experiment, providing undeniable proof that replacing smoking with smokeless nicotine dramatically reduces smoking-related disease, disability and premature deaths - a net gain for public health, while reducing expenditure. “With harm reduction now policy in Sweden, every public health decision will reflect this approach. Other countries should adopt Sweden’s model without further delay.” Rather than reducing tobacco use, Sweden now prioritises
Neos Kicks Off Global Indie Game Publishing Business25.3.2025 15:00:00 CET | Press Release
Neos has launched "IndieTech Games," a label dedicated to publishing high-quality indie games worldwide, including in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320035646/en/ IndieTechGames Neos entered the game development and publishing business for Nintendo Switch in 2019, starting with the release of "Shin chan: Me and the Professor on Summer Vacation - The Endless Seven-Day Journey" in Japan in 2021. The title later expanded to Asia, Europe, and North America in the following year, and eventually to the rest of the world, achieving cumulative shipments of over 500,000 units. The latest title, "Shin chan: Shiro and the Coal Town," has also been released globally and has been well received, following the success of its predecessor with cumulative shipments exceeding 300,000 units. Through the sales and marketing of our in-house developed titles, we have had more opportunities to engage with games from around
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom